Immunome Announces Proposed Public Offering of Common Stock

Impact · against what's priced in

Immunome shares face immediate downward pressure due to a $400 million common stock offering. This creates significant dilution for current shareholders, acting as a negative catalyst for the stock's valuation.

IMNM−0.60: No priced-in read yet
In context: The plan to issue and sell $400 million of common stock introduces immediate share dilution and increased supply of equity, typically leading to short-term price depreciation.
Read from the article alone

Immunome Announces Proposed Public Offering of Common Stock

public offering▲600%
biotech
IMNM
cancer therapy
capital raise
equity issuance

Top 1 mover · tap to explore

Immunome Announces Proposed Public Offering of Common Stock

What matters in this story

How each ticker is affected

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Immunome Announces Proposed Public Offering of Common Stock

What matters in this story

How each ticker is affected

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Track these names every morning.

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Kaplan Fox Announces the Lead Plaintiff Deadline of November 30, 2026 in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)

Immunome Announces Proposed Public Offering of Common Stock

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Immunome Announces Proposed Public Offering of Common Stock

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

Track these names every morning.

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Kaplan Fox Announces the Lead Plaintiff Deadline of November 30, 2026 in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)